Skip to main content

JDRF calls for AstraZeneca to explain type 1 diabetes drug withdrawal

JDRF is calling for AstraZeneca to clearly explain to people with type 1 diabetes why a drug licenced for the treatment of adults with the condition has been withdrawn.
JDRF logo placeholder for author profile picture
Kate Lawton 16 November 2021

A smartly-dressed woman having a discussion with a man.

AstraZeneca last week alerted clinicians that the drug dapagliflozin, also known by its brand name Forxiga, would be withdrawn immediately for type 1 diabetes use in the UK and EU.

The decision could affect up to 2,000 people in the UK with type 1 diabetes, even though, according to AstraZeneca, there are no new safety issues with the drug.

Clear explanation for withdrawal needed

JDRF is now calling on AstraZeneca to clearly explain to people affected by type 1 diabetes why the drug has been withdrawn for use treating that condition. The drug will continue to be available for other conditions including type 2 diabetes.

Dapagliflozin is a once-a-day pill which, when used alongside standard insulin therapy, significantly improves blood glucose management for many people with the life-threatening condition.

The first of its kind to be approved in the UK and EU for adults with type 1 diabetes, it is the only other drug besides insulin that has been licensed in the UK to treat type 1 diabetes.

Huge advancement in type 1 treatment

Its development was one of the biggest advancements in the treatment of type 1 diabetes since the discovery of insulin 100 years ago.

JDRF has long advocated for therapies that can improve the lives of those affected by type 1 diabetes, including treatments such as dapagliflozin. It was made available on the NHS as an ‘adjunct therapy’ to be used alongside insulin for people with type 1 diabetes by NICE in July 2019.

Managing type 1 diabetes with insulin alone is challenging and intensive, leaving a significant physical and mental burden upon the individual. Currently, just 30 per cent of people with type 1 diabetes reach their recommended blood glucose targets, putting them at greater risk of health complications.

Lower HbA1c levels

Dapagliflozin helps to reduce blood glucose levels by stopping the kidneys from reabsorbing glucose into the body. Instead, excess glucose is passed out in urine. Previous clinical trials showed that, when used alongside insulin, the drug helped people lower their HbA1c levels (a measure of average blood glucose levels) without increasing the incidence of hypoglycaemic events. Keeping HbA1c levels as close to the recommended target of 6.5% as possible is important in preventing long-term type 1 diabetes complications.

Karen Addington, UK Chief Executive of JDRF, said: “Dapagliflozin has been the first drug offered in 100 years since the discovery of insulin that has helped people with type 1 diabetes to manage their condition. It is appalling that it is now being withdrawn, even though many people with type 1 are finding it an effective and useful tool to help manage their glucose levels. JDRF asks AstraZeneca to explain to people in the UK affected by type 1 diabetes the reasons behind this withdrawal.”

Anyone affected by the withdrawal of dapagliflozin should contact their healthcare professional.

Related news

Read more
1 February 2024

Our letter to the producers of Would I Lie to You?

We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.

Read more
A doctor talking to a young woman holding a pen
23 January 2024

Parliamentary Inquiry calls for urgent action on type 1 and disordered eating

Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).

Read more
Hybrid closed loop technology
Type 1 technology
19 December 2023

NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales

In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.